Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents.
anabolic androgenic steroids
athlete biological passport
doping tests
testosterone
urinary steroid profile
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
18
10
2019
revised:
30
11
2019
accepted:
07
01
2020
pubmed:
12
1
2020
medline:
23
12
2020
entrez:
12
1
2020
Statut:
ppublish
Résumé
The use of anabolic androgenic steroids (AAS) and other performance enhancing substances can change over time, so there is a need to constantly update what substances are used and can be detected. Six women and 30 men anabolic androgenic steroid users were recruited who filled out an anonymous questionnaire about their use of performance enhancing substances during the past year. Sampling took place on a single occasion and included blood and urine collection. Our aim was to identify which doping agents can be detected in men and women self-reporting AAS use. The first choice of substances differed between men (testosterone) and women (oxandrolone). The use of growth hormones was reported among men (10%) and women (50%). Growth hormone releasing factors/secretagogs were reported by about ~ 20% in both genders. Nandrolone was the most frequently detected anabolic androgenic steroid even in those who did not report use in the past year. Of the current male testosterone users, 82% exhibited testosterone/epitestosterone (T/E) ratios of > 4. Men with current testosterone use displayed 4-fold and 6-fold higher median T/E, respectively, when compared with recent and previous testosterone users (P = 0.0001). Dermal testosterone use in women (n = 2) was not associated with a T/E ratio of > 4, but with supra-physiological total serum testosterone concentrations. Changes in gonadotropins and hematological parameters were associated with the time of the last anabolic androgenic steroid intake in men, whereas in women these biomarkers were within the normal range. This highlights gender specific differences and indicates the need for additional biomarkers in female athletes.
Substances chimiques
Anabolic Agents
0
Androgens
0
Steroids
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-523Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
Eklof AC, Thurelius AM, Garle M, Rane A, Sjoqvist F. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol. 2003;59(8-9):571-577.
Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4-13.
Sturmi JE, Diorio DJ. Anabolic agents. Clin Sports Med. 1998;17(2):261-282.
Ip EJ, Barnett MJ, Tenerowicz MJ, Kim JA, Wei H, Perry PJ. Women and anabolic steroids: an analysis of a dozen users. Clin J Sport Med. 2010;20(6):475-481.
Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011;31(8):757-766.
Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371(9627):1872-1882.
Evans NA. Gym and tonic: a profile of 100 male steroid users. Br J Sports Med. 1997;31(1):54-58.
Anawalt BD. Detection of anabolic androgenic steroid use by elite athletes and by members of the general public. Mol Cell Endocrinol. 2018;464:21-27.
Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am. 2010;39(1):59-73. viii-ix
World Anti-Doping Agency. TD2019IRMS. 2019. Available from: https://www.wada-ama.org/sites/default/files/td2019irms_final_eng_clean.pdf
Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, Rane A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab. 2008;93(7):2500-2506.
Handelsman DJ, Bermon S. Detection of testosterone doping in female athletes. Drug Test Anal. 2019;11(10):1566-1571.
Ponzetto F, Boccard J, Nicoli R, Kuuranne T, Saugy M, Rudaz S. Steroidomics for highlighting novel serum biomarkers of testosterone doping. Bioanalysis. 2019;11(12):1171-1187.
Christou GA, Christou MA, Ziberna L, Christou KA. Indirect clinical markers for the detection of anabolic steroid abuse beyond the conventional doping control in athletes. Eur J Sport Sci. 2019;19(9):1276-1286.
Rane A, Rosen T, Skarberg K, Heine L, Ljungdahl S. Steroids are a growing problem at gyms. Lakartidningen. 2013;110(39-40):1741-1746.
Garevik N, Borjesson A, Choong E, Ekstrom L, Lehtihet M. Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG CoA reductase in healthy men. Andrologia. 2016;48(5):595-600.
Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions. Rev Endocr Metab Disord. 2015;16(3):199-211.
Heckathorn DD. Snowball versus respondent-driven sampling. Sociol Methodol. 2011;41(1):355-366.
World Anti-Doping Agency. TD2016EEAS. 2016. Available from: https://www.wada-ama.org/sites/default/files/resources/files/wada-td2016eaas-eaas-measurement-and-reporting-en.pdf
Mullen JE, Thorngren JO, Schulze JJ, et al. Urinary steroid profile in females - the impact of menstrual cycle and emergency contraceptives. Drug Test Anal. 2017;9(7):1034-1042.
World Anti-Doping Agency. TD2018MRPL. 2018. Available from: https://www.wada-ama.org/sites/default/files/resources/files/td2018mrpl_v1_finaleng.pdf
World Anti-Doping Agency. TD2018DL. 2018. Available from: https://www.wada-ama.org/sites/default/files/resources/files/td2018dl_v1_en.pdf
Elmongy H, Masquelier M, Ericsson M. Development and validation of a UHPLC-HRMS method for the simultaneous determination of the endogenous anabolic androgenic steroids in human serum. J Chromatogr A. 2019;460686.
Lehtihet M, Bhuiyan H, Dalby A, Ericsson M, Ekstrom L. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers. Drug Test Anal. 2019;11(3):411-421.
World Anti-Doping Agency. Prohibited list. 2019. Available from: https://www.wada-ama.org/sites/default/files/wada_2019_english_prohibited_list.pdf
Miller GD, Nair V, Morrison MS, Summers M, Willick SE, Eichner D. Intranasal delivery of Natesto(R) testosterone gel and its effects on doping markers. Drug Test Anal. 2016;8(11-12):1197-1203.
Mullen J, Borjesson A, Hopcraft O, et al. Sensitivity of doping biomarkers after administration of a single dose testosterone gel. Drug Test Anal. 2018;10(5):839-848.
Choong E, Schulze JJ, Ericsson M, Rane A, Ekstrom L. Discordant genotyping results using DNA isolated from anti-doping control urine samples. Drug Test Anal. 2017;9(7):994-1000.
Okano M, Ueda T, Nishitani Y, Kano H, Ikekita A, Kageyama S. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse. Drug Test Anal. 2013;5(3):166-181.
Strahm E, Mullen JE, Garevik N, et al. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism. Drug Test Anal. 2015;7(11-12):1063-1070.
Garevik N, Strahm E, Garle M, et al. Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. J Steroid Biochem Mol Biol. 2011;127(3-5):295-300.
Hirschberg AL, Elings Knutsson J, Helge T, et al. Effects of moderately increased testosterone concentration on physical performance in young women: a double blind, randomised, placebo controlled study. Br J Sports Med. 2019;10(15).
Ponzetto F, Mehl F, Boccard J, et al. Longitudinal monitoring of endogenous steroids in human serum by UHPLC-MS/MS as a tool to detect testosterone abuse in sports. Anal Bioanal Chem. 2016;408(3):705-719.
Ankarberg-Lindgren C, Norjavaara E. Changes of diurnal rhythm and levels of total and free testosterone secretion from pre to late puberty in boys: testis size of 3 ml is a transition stage to puberty. Eur J Endocrinol. 2004;151(6):747-757.
Handelsman DJ. Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science. Hum Reprod. 2017;32(6):1147-1150.
Rezaii T, Gustafsson TP, Axelson M, et al. Circulating androgens and SHBG during the normal menstrual cycle in two ethnic populations. Scand J Clin Lab Invest. 2017;77(3):184-189.
Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49(8):1381-1395.
Garevik N, Rane A, Bjorkhem-Bergman L, Ekstrom L. Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men. Subst Abuse Rehabil. 2014;5:121-127.
Lood Y, Eklund A, Garle M, Ahlner J. Anabolic androgenic steroids in police cases in Sweden 1999-2009. Forensic Sci Int. 2012;219(1-3):199-204.
Krug O, Thomas A, Walpurgis K, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol. 2014;70(11):1303-1311.
Weber C, Krug O, Kamber M, Thevis M. Qualitative and Semiquantitative analysis of doping products seized at the Swiss border. Subst Use Misuse. 2017;52(6):742-753.
Martello S, Felli M, Chiarotti M. Survey of nutritional supplements for selected illegal anabolic steroids and ephedrine using LC-MS/MS and GC-MS methods, respectively. Food Addit Contam. 2007;24(3):258-265.
Bagchus WM, Smeets JM, Verheul HA, De Jager-Van Der Veen SM, Port A, Geurts TB. Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men. J Clin Endocrinol Metab. 2005;90(5):2624-2630.
Borjesson A, Garevik N, Dahl ML, Rane A, Ekstrom L. Recruitment to doping and help-seeking behavior of eight female AAS users. Subst Abuse Treat Prev Policy. 2016;11:1-6.
Pope HG, Katz DL Jr. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375-382.
World Anti-Doping Agency. Anti-Doping Testing Figures by Laboratory. 2017. Available from: https://www.wada-ama.org/sites/default/files/resources/files/2017_anti-doping_testing_figures_en_0.pdf
Mullen J, Gårevik N, Schulze J, Rane A, Bergman L, Ekström L. Perturbation of the hematopoietic profile by anabolic androgenic steroids. J Hormones. 2014;2014:510257. https://doi.org/10.1155/2014/510257
Chang S, Munster AB, Gram J, Sidelmann JJ. Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis. Semin Thromb Hemost. 2018;44(8):734-746.
Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European network for the investigation of gender incongruence. Andrology. 2018;6(3):446-454.